Oncology and Hematology

Episodes 46-60 of 231

• 

  RestartResume

  Safety First: Navigating CELMoD-Associated Toxicities

  MinuteCE®

  Safety First: Navigating CELMoD-Associated Toxicities

  • 

    

    Joshua Richter, MD

    Peer

  • 

    

    Noopur Raje, MD

    Peer

  1.00 program credits

• 

  RestartResume

   Real-World Ready: Practical Tips for Community Oncologists

  MinuteCE®

   Real-World Ready: Practical Tips for Community Oncologists

  • 

    

    Joshua Richter, MD

    Peer

  • 

    

    Sagar Lonial, MD, FACP

    Peer

  1.00 program credits

• 

  RestartResume

  Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma

  MinuteCE®

  Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma

  • 

    

    Joshua Richter, MD

    Peer

  • 

    

    Noopur Raje, MD

    Peer

  1.00 program credits

• 

  RestartResume

  Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs

  MinuteCE®

  Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs

  • 

    

    Joshua Richter, MD

    Peer

  • 

    

    Sagar Lonial, MD, FACP

    Peer

  1.00 program credits

• 

  RestartResume

  Next-Generation Innovations: The Future of CELMoDs in Myeloma

  MinuteCE®

  Next-Generation Innovations: The Future of CELMoDs in Myeloma

  • 

    

    Noopur Raje, MD

    Peer

  1.00 program credits

• 

  RestartResume

  Advanced Therapeutic Strategies and Resistance Mechanisms in CLL

  CME/CE

  Advanced Therapeutic Strategies and Resistance Mechanisms in CLL

  • 

    

    Shankara Paneesha, MD FRCP FRCPath

    Peer

  0.25 credits
• advertisement

• 

  MinuteCE®

  Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma

  • 

    

    John M. Kirkwood, MD

    Peer

  • 

    

    Paolo A. Ascierto, MD

    Peer

  • 

    

    Hussein Tawbi, MD, PhD

    Peer

  • 

    

    Sapna Patel, MD

    Peer

  1.00 credits 10 episodes

• 

  MinuteCE®

  Reimagining Lung Cancer Treatment: A Journey Through New and Emerging Therapeutics Related to the Care of Patients with Small Cell and Non-Small Cell Lung Cancer

  • 

    

    Stephen Liu, MD

    Peer

  • 

    

    Joshua K. Sabari, MD

    Peer

  • 

    

    Susan Scott, MD

    Peer

  1.25 credits 9 episodes

• 

  RestartResume

  Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)

  MinuteCE®

  Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)

  • 

    

    Stephen Liu, MD

    Peer

  • 

    

    Joshua K. Sabari, MD

    Peer

  • 

    

    Susan Scott, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Novel Therapies in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

  MinuteCE®

  Novel Therapies in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

  • 

    

    Stephen Liu, MD

    Peer

  • 

    

    Joshua K. Sabari, MD

    Peer

  • 

    

    Susan Scott, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Applications of Emerging Data in Resectable NSCLC

  MinuteCE®

  Applications of Emerging Data in Resectable NSCLC

  • 

    

    Stephen Liu, MD

    Peer

  • 

    

    Joshua K. Sabari, MD

    Peer

  • 

    

    Susan Scott, MD

    Peer

  1.25 program credits

• 

  RestartResume

  The Current Therapeutic Landscape in Unresectable Stage III NSCLC

  MinuteCE®

  The Current Therapeutic Landscape in Unresectable Stage III NSCLC

  • 

    

    Stephen Liu, MD

    Peer

  • 

    

    Joshua K. Sabari, MD

    Peer

  • 

    

    Susan Scott, MD

    Peer

  1.25 program credits
• advertisement

• 

  RestartResume

  Strategies in EGFR-mutated Unresectable Stage III NSCLC

  MinuteCE®

  Strategies in EGFR-mutated Unresectable Stage III NSCLC

  • 

    

    Stephen Liu, MD

    Peer

  • 

    

    Joshua K. Sabari, MD

    Peer

  • 

    

    Susan Scott, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC

  MinuteCE®

  Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC

  • 

    

    Stephen Liu, MD

    Peer

  • 

    

    Joshua K. Sabari, MD

    Peer

  • 

    

    Susan Scott, MD

    Peer

  1.25 program credits

• 

  RestartResume

  HER2-Driven Strategies in Metastatic NSCLC

  MinuteCE®

  HER2-Driven Strategies in Metastatic NSCLC

  • 

    

    Stephen Liu, MD

    Peer

  • 

    

    Joshua K. Sabari, MD

    Peer

  • 

    

    Susan Scott, MD

    Peer

  1.25 program credits

• Prev
• 1
• 2
• 3
• 4
• 5
• 6
• …
• 15
• 16
• Next